More research on the relationship between the decreased MYEF2 expression and resistance to anti-PD1 and CTLA4 therapy may help to improve the efficacy of anti-PD1 and CTLA4 therapy in GBM patients. This evidence concerns the gene MYEF2 and glioblastoma.